Otsuka Pharmaceutical Company, Ltd. (Otsuka)
Akebia collaborates with Otsuka on the development and, upon approval by the FDA, the commercialization of vadadustat in the United States. In addition, Akebia and Otsuka have a collaboration and license agreement for the development and commercialization of vadadustat in Europe, China, Russia, Canada, Australia, the Middle East and certain other territories. Akebia will continue to lead the ongoing global Phase 3 development program for vadadustat.
Mitsubishi Tanabe Pharma Corporation (MTPC)
Akebia has a collaboration agreement with MTPC, providing MTPC with exclusive development and commercialization rights to vadadustat in Japan and certain other Asian countries.
Akebia has provided Vifor Pharma an exclusive license to sell vadadustat solely to Fresenius Kidney Care Group LLC, or FKC, an affiliate of Fresenius Medical Care North America, for use solely within its dialysis facilities in the U.S., subject to FDA approval. Akebia retains all rights to commercialize vadadustat for use in the non-dialysis dependent market and in other dialysis organizations in the United States, which will be done in collaboration with Otsuka following FDA approval.
For more information on partnering opportunities with Akebia, please fill out our contact form.
Vadadustat is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.